Global Preventive and Therapeutic Vaccine Market size is poised to experience high growth, primarily because of its fast-growing nature and expanding market size. Vaccine developments have been considerably increasing since recent past and their adoption is also rising in various regions across the globe. Practices by the major companies, such as consistent research and innovation and development for introducing recent technologies to curb expense and reduce time will spur vaccine market worldwide.
Increasing government funding for vaccine development, rising R&D investments, the introduction of faster vaccine development technologies, and improvements in vaccine design are some of the factors, which will fuel market growth over the coming years. However, the high cost of vaccine storage and transportation and stringent regulations for the approval of vaccines will hamper the market expansion.
Global preventive and therapeutic vaccine market is broadly classified into preventive vaccine market and therapeutic vaccine market. Based on the product type, preventive vaccine market is segmented into pediatric and adult vaccines and therapeutic vaccine is segmented into neurological disease vaccines, autoimmune disease vaccines, infectious disease vaccines, and cancer vaccines.
Soaring prevalence of diseases among children is resulting in the implementation of awareness programs by governments across the globe. Moreover, significant advancements in vaccinology, such as the emergence, development, and usage of hepatitis B vaccine, should augment the business growth over the coming years.
Strategies adopted by major vendors in the market, such as the development of improved influenza vaccine that broaden vaccine-induced immunity, enhancing the vaccine immunogenicity, and introducing alternative delivery will result in greater adoption of influenza vaccine in future.
A significant factor proliferating the demand for certain vaccines is high effectiveness; for example, the experimental shingles vaccine protects about 90% of adults, the present Zostovax vaccine reduces the risk of shingles by about half and immunity wanes within five years. In coming years, more vaccines will have better effectiveness and therefore, these vaccines will experience high adoption rates.
Based on the technology type, the vaccine market is segmented into live attenuated, toxoid, conjugate, inactivated & subunit, and recombinant. The conjugate vaccines hold the largest market share; the growth of this segment is associated with the massive government support for vaccine development and rising investments in R&D.
The U.S. preventive and therapeutic vaccine market enjoys the major share because of the presence of advanced and active R&D establishment. It dominates the therapeutic vaccine market, which is driven by large pharmaceutical industry base, best-in-class healthcare infrastructure, and high spending on healthcare by the citizens. The government support for research and development of vaccines, investments for vaccine research, and ubiquity of different diseases fuel the growth of this region.
Europe preventive and therapeutic vaccine market is the second largest market after North America. Research, innovation, and development conducted by MNCs in the field of vaccine production by utilizing their deep expertise are advantages for this region. Increasing prevalence of diseases in children and adults will generate demand for more preventive vaccine in coming years; to cater to this demand, big companies, such as Pfizer, Merck, Sanofi, and GlaxoSmithKline, will play a key role in the future.
In the APAC preventive and therapeutic vaccine market, the growing incidences of cancer & HIV cases will give rise to the demand for vaccine and therefore boost the market growth. Improving healthcare sector, increasing healthcare expenditure, and government initiatives will render a high impact on adoption rates of vaccines. WHO estimates a huge potential for the market with the arrival of new improved preventive and therapeutic vaccines. China and India are expected to witness a boom in demand and are expected to attain maximum growth over the next 10 years, owing to the escalating prevalence of various infectious diseases and improving economic indicators.
Latin America therapeutic vaccines targeting cancers and allergies offer vast opportunities for fresh players entering this regional market. First FDA-approved therapeutic vaccine, Provenge by Dendreon, treating prostate cancer acknowledged the potential of vaccines in therapeutics. In the coming years, it is expected that the industry will experience improvements in vaccine delivery methodologies, vaccine design, manufacturing in a large-scale process, and development of personalized vaccines. Therapeutic vaccines address the demand for safe and cost-effective drugs for the treatment of cancer and HIV, fueling the market growth.
Saudi Arabia and South Africa dominates the Middle East & Africa preventive and therapeutic vaccine market. R&D funding for diseases, such as HIV and cancer, by the government offers a novel opportunity for the vaccine market. Wide usage of vaccines includes, inactivated, live attenuated, toxoid, subunit, conjugate, dendritic cell, and synthetic. Preventive vaccine is the leading type due to high awareness among people.
Some of the major players in the global preventive and therapeutic vaccine market are Sanofi Pasteur, Merck & Co., Pfizer, and GlaxoSmithKline. The largest players account for approximately 80% of the global revenue. AstraZeneca, Johnson & Johnson, CSL, and Emergent Biosolutions are the other notable industry players.